Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144527 · ClinicalTrials.gov registry record · NA
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
A NA study of Aging and Frailty, sponsored by Scott Silveira.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07144527: Recruiting NA study of Aging and Frailty, sponsored by Scott Silveira.
NCT07144527 is a NA study of Aging and Frailty that is actively recruiting participants, run by Scott Silveira. The registered enrollment target is 40 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07144527, a NA study of Aging and Frailty, is actively recruiting participants, sponsored by Scott Silveira.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Primary Outcome
Duration (in seconds) that participants can sustain a constant submaximal workload on a cycle ergometer until volitional fatigue. This is a validated surrogate for submaximal exercise tolerance.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT NMN, betaine, low-dose hydrogen peroxide (EGA)
- DIETARY_SUPPLEMENT Nicotinamide Mononucleotide (NMN)
Study Locations (1)
California
- Medical Office of Dr. Robert Huizenga MD - Beverly Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-21 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT07144527 shows while recruiting
NCT07144527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07144527 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07144527 about?
NCT07144527 is a clinical study titled "Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults". This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolera...
What is the current status of trial NCT07144527?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-02-21. Estimated completion is 2027-01-01.
What conditions does trial NCT07144527 study?
This clinical trial studies the following conditions: Aging, Frailty, Healthy Male and Female Subjects, Exercise Tolerance.
What interventions are being tested in trial NCT07144527?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), NMN, betaine, low-dose hydrogen peroxide (EGA) (DIETARY_SUPPLEMENT), Nicotinamide Mononucleotide (NMN) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07144527?
This trial is sponsored by Scott Silveira, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144527 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07144527's enrollment target sits among peer trials
40 173rd of 262 higher than 84 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI